文献速递急性肾损伤

免疫检查点抑制剂治疗患者急性肾损伤的发生率、病因及危险因素

The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
PubMed 文献 · Clin J Am Soc Nephrol · 2019-10-31

该研究纳入2011年5月至2016年12月在麻省总医院接受免疫检查点抑制剂治疗的1016例患者,评估急性肾损伤(AKI)的频率、严重程度、病因及预测因素。结果显示17%患者发生AKI,8%为持续性AKI,3%为潜在检查点抑制剂相关AKI;基线使用质子泵抑制剂与持续性AKI相关。

要点

  • 接受检查点抑制剂治疗的患者中AKI常见,17%发生AKI,8%为持续性AKI。
  • 持续性AKI病因异质,需全面评估,包括潜在药物性肾损伤。
  • 基线质子泵抑制剂使用与持续性AKI相关,需进一步明确其作用。

核心结论

  • 免疫检查点抑制剂治疗患者中AKI常见,持续性AKI病因多样,需全面评估。
  • 基线质子泵抑制剂使用与持续性AKI相关,其作用需进一步明确。

研究设计与样本

  • 回顾性队列研究,纳入2011年5月至2016年12月在麻省总医院接受检查点抑制剂治疗的1016例患者。
  • 基线血清肌酐取检查点抑制剂开始前6个月平均值,与开始治疗后12个月内所有肌酐值比较。
  • AKI定义采用KDIGO肌酐倍数变化标准;持续性AKI指持续至少3天,为主要结局。

主要发现

  • 1016例患者平均年龄63岁(SD 13),61%为男性,91%为白人;平均基线肌酐0.9 mg/dl(SD 0.4),169例(17%)基线存在CKD(eGFR<60 ml/min per 1.73 m2)。
  • 169例(17%)发生AKI(12个月内肌酐升至基线至少1.5倍);82例(8%)发生持续性AKI,30例(3%)为潜在检查点抑制剂相关AKI。
  • 首次持续性AKI平均发生在检查点抑制剂开始后106天(SD 85);16例(2%)发生3期持续性AKI,4例需透析。
  • 基线质子泵抑制剂使用与持续性AKI相关。

临床怎么用

  • 接受检查点抑制剂治疗的患者应监测肾功能,警惕AKI发生。
  • 对持续性AKI应全面评估病因,包括药物性肾损伤。
  • 关注基线质子泵抑制剂使用等潜在可调整因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Immune checkpoint inhibitor use in oncology is increasing rapidly. We sought to determine the frequency, severity, cause, and predictors of AKI in a real-world population receiving checkpoint inhibitors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We included all patients who received checkpoint inhibitor therapy from May 2011 to December 2016 at Massachusetts General Hospital. Baseline serum creatinine, averaged 6 months before checkpoint inhibitor start date, was compared with all subsequent creatinine values within 12 months of starting therapy. AKI was defined by Kidney Disease: Improving Global Outcomes criteria for fold changes in creatinine from baseline. Sustained AKI events lasted at least 3 days and was our primary outcome. The cause of sustained AKI was determined by chart review. Cumulative incidence and subdistribution hazard models were used to assess the relationship between baseline demographics, comorbidities, and medications, and sustained AKI and potential checkpoint inhibitor-related AKI. RESULTS: We included 1016 patients in the analysis. Average age was 63 (SD 13) years, 61% were men, and 91% were white. Mean baseline creatinine was 0.9 mg/dl (SD 0.4 mg/dl), and 169 (17%) had CKD (eGFR<60 ml/min per 1.73 m2) at baseline. A total of 169 patients (17%) experienced AKI, defined by an increase in creatinine at least 1.5 times the baseline within 12 months; 82 patients (8%) experienced sustained AKI and 30 patients (3%) had potential checkpoint inhibitor-related AKI. The first episode of sustained AKI occurred, on average, 106 days (SD 85) after checkpoint inhibitor initiation. Sixteen (2%) patients experienced stage 3 sustained AKI and four patients required dialysis. Proton pump inhibitor use at baseline was associated with sustained AKI. CONCLUSIONS: AKI is common in patients receiving checkpoint inhibitor therapy. The causes of sustained AKI in this population are heterogenous and merit thorough evaluation. The role of PPI and other nephritis-inducing drugs in the development of sustained AKI needs to be better defined.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Seethapathy H, Zhao S, Chute DF, et al. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019. PMID: 31672794. doi:10.2215/CJN.00990119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。